Uni Targeting Research AS is a holding company that provides the biopharmaceutical industry with tools and services for mammalian cell-line based development procedures and production processes. It offers upstream solutions to reduce complementary deoxyribonucleic acid and mammalian cell-line based timelines and increase protein production yields. Its technology enables both enhanced synthesis/secretion of naturally secreted proteins, and secretion of intracellular proteins. Its services include vector improvement, tailor-made vectors, and tool proteins. The company was founded by Ian Fraser Pryme, John E. Hesketh, Albert Tauler, and Beate Stern in 2001 and is headquartered in Bergen, Norway.

Kumho Petrochemical is a manufacturer of synthetic resins, fine chemicals, energy, building materials and other plastic materials.

Genesis Research Institute offers research and technical information support related to forecasting future societal conditions services.

Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA.

DSM IP Assets BV, a subsidiary of Koninklijke DSM NV, is a company headquartered in Heerlen, the Netherlands, that develops and produces nutrition, pharmacy & material science products.

US Agriculture LLC provides investment services. It operates and manage farmland assets and portfolios, develop and implement farmland investment strategies, underwrite and acquire farmland assets across a variety of regions and crop types, develop and implement efficient and effective reporting processes, design and implement investment policies, develop and implement asset allocation strategies, create and implement tools for market and asset targeting, and create and implement portfolio optimization tools and processes. The company was founded in 2015 and is headquartered in Indianapolis, IN.

Toyota is a company that is operating its business with a focus on vehicle production and sales. Toyota completed its A1 prototype passenger car and the G1 truck in 1935. The first export of a Toyota car (G1 truck) occurred in 1936 and Toyota established its logo during the same year. By 1938, it started the production of the G1 truck. In 1957, Toyota exported the Japanese passenger car ‘Crown’ to the United States for the first time. Toyota Motor Sales, U.S.A. was also established in 1957. In 1985, Toyota’s cumulative exports reached 20 million units, and its annual overseas output exceeded 3 million units in 1999. As of the end of Dec. 2013, Toyota conducts its business worldwide with 52 overseas manufacturing companies in 27 countries and regions. Toyota's vehicles are sold in more than 160 countries and regions. Toyota today manufactures a diverse line-up of vehicles all over the world, including sport utility vehicles, commercial vehicles, and more. Toyota was founded in 1937 by Kiichiro Toyoda and is headquartered in Aichi.

POSCO Holdings Inc. engages in the production of steel products. It operates through the following divisions: Steel, Engineering & Construction and Trading. The Steel division produces cold rolled, hot rolled and stainless steel products, plates, wire rods and silicon steel sheets. The Engineering & Construction division engages in the planning, designing and construction of industrial plants, civil engineering projects, commercial and residential buildings. The Trading division exports and imports steel products and raw materials. The company was founded by Tae-Joon Park on April 1, 1968 and is headquartered in Seoul, South Korea.

Xiamen Overseas Chinese Electronic Co., Ltd. engages in the manufacture and sale of color television sets and automobile monitors. It also manufactures interactive TV, high-definition TV, radio and sound recording equipment, laser audio-visual equipment as well as communication equipment, including cordless, video and global telephone, multimedia computer and peripherals. The company was founded on December 19, 1985 and is headquartered in Xiamen, China.

Abraxis BioScience LLC, part of Bristol Myers Squibb Co., is a company headquartered in Los Angeles, CA, involved in commercial physical and biological research.

Qingdao Weilan Biological Group Co., Ltd., established on 2007-08-22, Business scope includes licensed projects:Import and export;Technology Import and Export;food business(Selling prepackaged food);Catering Services;Food Internet Sales;Food Internet Sales(Selling prepackaged food);food business;Health food sales;Sales of formula food for special medical purposes;Veterinary drug business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Research and development of bio-based materials technology;R&D of industrial enzyme preparations;Biomass liquid fuel production process research and development;Bio-feed R&D;Bio-organic fertilizer research and development;Fermentation process optimization technology research and development;Biochemical product technology research and development;Extraction of marine bioactive substances,purification,Synthesis technology research and development;R&D and application of cell technology;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Food Additive Sales;Engage in investment activities with own funds;Animal Husbandry and Fishery Feed Sales;Feed Raw Material Sales;Feed Additive Sales;business management;property management;Conference and Exhibition Services;internet sales(Except for products that require a license for sale);Cosmetics Wholesale;Cosmetics Retail;Sales of hygiene products and single-use medical products;Personal Hygiene Sales;Daily necessities sales;Daily necessities wholesale;Daily miscellaneous goods sales;Pet Food and Supplies Wholesale;Pet food and supplies retail;Information Consulting Service(Not including licensing information consulting services);Information Technology Consulting Services;Health Consulting Services(Does not include medical services);Development of Human Gene Diagnosis and Therapy Technology;Chemical product sales(No licensed chemical products);Sales of Class I Medical Devices;Disinfectant sales(Free of Hazardous Chemicals);Business Management Consulting;Educational Consulting Services(Education and training activities that do not include licensing approval).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

QBI Enterprises Ltd. is an Israeli private company located in Ness Ziona. The firm develops pharmaceutical therapeutics.

Anhui Good Hope Baby Safety Technology Co., Ltd., established on 2010-12-08, The business scope includes child safety seats and accessories,Air seat,Children's dining chair,Baby carriage production and sales;disposable mask(non-medical),dust mask,Protective equipment for medical staff,Production and sales of wet paper and diapers;Auto Accessories,rubber products,Glass product,Cotton,Leather,Processing and sales of daily necessities;clothing,textile,Textile Raw Materials,Mechanical equipment and spare parts,Sales of chemical raw materials and auxiliary materials;Import and export business of goods and technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Spark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases. The founding team includes scientists who have led the advancement of gene therapy over the past two decades, establishing human proof of concept of the expression of gene therapy in the eye and liver. Spark’s robust pipeline includes SPK-RPE65, a fully enrolled, pivotal Phase 3 program in blindness due to mutations in the RPE65 gene, SPK-CHM for the treatment of choroideremia, and SPK-FIX, a program for the potential treatment of hemophilia B through a global collaboration with Pfizer Inc., as well as preclinical programs to address neurodegenerative diseases and other retinal degenerative diseases and hematologic disorders. Spark has rights to a proprietary manufacturing platform that has a track record supporting clinical studies across diverse therapeutic areas and routes of administration. Spark’s expertise across research, clinical, regulatory and manufacturing builds on a legacy of innovation and excellence in gene therapy established by Spark’s team while at The Children’s Hospital of Philadelphia Center for Cellular and Molecular Therapeutics.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.